Randomized, Double-Blind, Placebo-Controlled International Clinical Trial of the AMPAKINE^® CX516 in Elderly Participants with Mild Cognitive Impairment

By Johnson S.A.   Simmon V.F.  

Journal of Molecular Neuroscience, Vol. 19, Iss. 1-2, 2002-10 ,pp. : 197-200

Humana Press, Inc

Access to resources Recommend Favorite

CHF5074 Reduces Biomarkers of Neuroinflammation in Patients with Mild Cognitive Impairment: A 12-Week, Double-Blind, Placebo- Controlled Study

By  

Current Alzheimer Research, Vol. 10, Iss. 7, 2013-09 ,pp. : 742-753

Bentham Science Publishers

Access to resources Recommend Favorite

Training of attentional control in mild cognitive impairment with executive deficits: Results from a double-blind randomised controlled study

By Gagnon Lyssa G.   Belleville Sylvie  

Neuropsychological Rehabilitation, Vol. 22, Iss. 6, 2012-12 ,pp. : 809-835

Routledge Ltd

Access to resources Recommend Favorite

Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease Already Receiving a Cholinesterase Inhibitor: A Randomized, Double-Blind, Placebo-Controlled Trial

By  

Current Alzheimer Research, Vol. 5, Iss. 1, 2008-02 ,pp. : 83-89

Bentham Science Publishers

Access to resources Recommend Favorite

Cerebrospinal and peripheral human immunodeficiency virus type 1 load in a multisite, randomized, double-blind, placebo-controlled trial of d-Ala 1 -peptide T-amide for HIV-1-associated cognitive-motor impairment

By Goodkin Karl   Vitiello Benedetto   Lyman William   Asthana Deshratn   Atkinson J   Heseltine Peter   Molina Rebeca   Zheng Wenli   Khamis Imad   Wilkie Frances   Shapshak Paul  

Journal of NeuroVirology, Vol. 12, Iss. 3, 2006-07 ,pp. : 178-189

Ashgate Publishing Ltd

Access to resources Recommend Favorite